The United Therapeutics Corporation special call on September 28, 2025, focused on presenting results from the TETON-2 trial, which showed treprostinil, delivered via Tyvaso, significantly improved forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). The company views these findings as a significant milestone, demonstrating strong evidence of therapeutic benefit with a well-tolerated safety profile, and stated it would seek regulatory approval for the IPF indication.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.